Rothschild Investment LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

Rothschild Investment LLC’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$645	Buy	210 +70	+50%	+$271	﹤0.01%	3038
2025 Q4	$573	Buy	140 +80	+133%	+$396	﹤0.01%	2886
2025 Q3	$293	Sell	60 -540	-90%	-$2.84K	﹤0.01%	2947
2025 Q2	$3.04K	Sell	600 -125	-17%	-$614	﹤0.01%	1780
2025 Q1	$3.83K	Buy	725 +350	+93%	+$2.55K	﹤0.01%	1567
2024 Q4	$2.54K	Buy	375 +220	+142%	+$1.48K	﹤0.01%	1658
2024 Q3	$1.02K	Buy	155 +80	+107%	+$573	﹤0.01%	2153
2024 Q2	$563	Buy	75 +65	+650%	+$567	﹤0.01%	1936
2024 Q1	$100	Buy	+10	New	+$111	﹤0.01%	2213

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rothschild Investment LLC's RXRX Position: Q1 2026 in Review

Rothschild Investment LLC increased its Recursion Pharmaceuticals (RXRX) stake by 50% in Q1 2026, buying an estimated $271 and bringing the position to 210 shares worth $645. The position accounts for ﹤0.01% of the portfolio, ranked #3038.

Rothschild Investment LLC first reported a position in RXRX in Q1 2024 and has held it in 9 quarters since. The position peaked at $3.83K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Rothschild Investment LLC held 210 shares of Recursion Pharmaceuticals worth $645 as of Q1 2026.
Rothschild Investment LLC bought 70 Recursion Pharmaceuticals shares in Q1 2026, an estimated $271.
Recursion Pharmaceuticals made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #3038 holding.
Rothschild Investment LLC first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Rothschild Investment LLC's Recursion Pharmaceuticals position peaked at $3.83K in Q1 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.